nodes	percent_of_prediction	percent_of_DWPC	metapath
Goserelin—LHCGR—corpus luteum—uterine cancer	0.236	0.78	CbGeAlD
Goserelin—LHCGR—renal system—uterine cancer	0.0189	0.0625	CbGeAlD
Goserelin—LHCGR—female reproductive system—uterine cancer	0.0151	0.05	CbGeAlD
Goserelin—LHCGR—female gonad—uterine cancer	0.0137	0.0455	CbGeAlD
Goserelin—GNRHR—female reproductive system—uterine cancer	0.00973	0.0322	CbGeAlD
Goserelin—GNRHR—female gonad—uterine cancer	0.00886	0.0293	CbGeAlD
Goserelin—LHCGR—Ovarian Infertility Genes—MLH1—uterine cancer	0.00518	0.144	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—PGR—uterine cancer	0.00491	0.136	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—ESR2—uterine cancer	0.00432	0.12	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—CYP19A1—uterine cancer	0.00392	0.109	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—SMAD3—uterine cancer	0.00321	0.089	CbGpPWpGaD
Goserelin—LHCGR—Arf6 signaling events—MET—uterine cancer	0.00245	0.0679	CbGpPWpGaD
Goserelin—LHCGR—Ovarian Infertility Genes—CDKN1B—uterine cancer	0.00178	0.0494	CbGpPWpGaD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000372	0.0103	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKR1B10—uterine cancer	0.000357	0.0099	CbGpPWpGaD
Goserelin—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000357	0.000539	CcSEcCtD
Goserelin—Renal impairment—Doxorubicin—uterine cancer	0.000357	0.000539	CcSEcCtD
Goserelin—Malaise—Etoposide—uterine cancer	0.000355	0.000537	CcSEcCtD
Goserelin—Leukopenia—Etoposide—uterine cancer	0.000353	0.000533	CcSEcCtD
Goserelin—Body temperature increased—Dactinomycin—uterine cancer	0.000351	0.00053	CcSEcCtD
Goserelin—Abdominal pain—Dactinomycin—uterine cancer	0.000351	0.00053	CcSEcCtD
Goserelin—Cardiac failure—Doxorubicin—uterine cancer	0.000348	0.000525	CcSEcCtD
Goserelin—Mood swings—Epirubicin—uterine cancer	0.000347	0.000525	CcSEcCtD
Goserelin—Lethargy—Doxorubicin—uterine cancer	0.000346	0.000523	CcSEcCtD
Goserelin—Cerebrovascular accident—Doxorubicin—uterine cancer	0.000346	0.000523	CcSEcCtD
Goserelin—Cough—Etoposide—uterine cancer	0.000344	0.000519	CcSEcCtD
Goserelin—Convulsion—Etoposide—uterine cancer	0.000341	0.000516	CcSEcCtD
Goserelin—Hypertension—Etoposide—uterine cancer	0.00034	0.000514	CcSEcCtD
Goserelin—Osteoarthritis—Doxorubicin—uterine cancer	0.000339	0.000513	CcSEcCtD
Goserelin—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000338	0.000511	CcSEcCtD
Goserelin—Dry skin—Epirubicin—uterine cancer	0.000336	0.000508	CcSEcCtD
Goserelin—Chest pain—Etoposide—uterine cancer	0.000335	0.000507	CcSEcCtD
Goserelin—Affect lability—Doxorubicin—uterine cancer	0.000334	0.000504	CcSEcCtD
Goserelin—Migraine—Doxorubicin—uterine cancer	0.000334	0.000504	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000333	0.000503	CcSEcCtD
Goserelin—Discomfort—Etoposide—uterine cancer	0.000331	0.000501	CcSEcCtD
Goserelin—Breast disorder—Epirubicin—uterine cancer	0.000331	0.000501	CcSEcCtD
Goserelin—Hypersensitivity—Dactinomycin—uterine cancer	0.000327	0.000494	CcSEcCtD
Goserelin—Confusional state—Etoposide—uterine cancer	0.000324	0.00049	CcSEcCtD
Goserelin—Anaphylactic shock—Etoposide—uterine cancer	0.000322	0.000486	CcSEcCtD
Goserelin—Mood swings—Doxorubicin—uterine cancer	0.000321	0.000486	CcSEcCtD
Goserelin—Infection—Etoposide—uterine cancer	0.000319	0.000483	CcSEcCtD
Goserelin—Asthenia—Dactinomycin—uterine cancer	0.000319	0.000481	CcSEcCtD
Goserelin—Influenza—Epirubicin—uterine cancer	0.000317	0.000479	CcSEcCtD
Goserelin—Thrombocytopenia—Etoposide—uterine cancer	0.000315	0.000476	CcSEcCtD
Goserelin—Tachycardia—Etoposide—uterine cancer	0.000314	0.000474	CcSEcCtD
Goserelin—Skin disorder—Etoposide—uterine cancer	0.000312	0.000472	CcSEcCtD
Goserelin—Dry skin—Doxorubicin—uterine cancer	0.000311	0.00047	CcSEcCtD
Goserelin—Hyperhidrosis—Etoposide—uterine cancer	0.000311	0.00047	CcSEcCtD
Goserelin—Angina pectoris—Epirubicin—uterine cancer	0.000309	0.000466	CcSEcCtD
Goserelin—Breast disorder—Doxorubicin—uterine cancer	0.000307	0.000463	CcSEcCtD
Goserelin—Anorexia—Etoposide—uterine cancer	0.000307	0.000463	CcSEcCtD
Goserelin—Bronchitis—Epirubicin—uterine cancer	0.000305	0.00046	CcSEcCtD
Goserelin—Diarrhoea—Dactinomycin—uterine cancer	0.000304	0.000459	CcSEcCtD
Goserelin—Hypotension—Etoposide—uterine cancer	0.0003	0.000454	CcSEcCtD
Goserelin—Dysuria—Epirubicin—uterine cancer	0.000296	0.000448	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—RNF43—uterine cancer	0.000296	0.0082	CbGpPWpGaD
Goserelin—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000295	0.000445	CcSEcCtD
Goserelin—LHCGR—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000294	0.00816	CbGpPWpGaD
Goserelin—Influenza—Doxorubicin—uterine cancer	0.000293	0.000443	CcSEcCtD
Goserelin—Pollakiuria—Epirubicin—uterine cancer	0.000293	0.000442	CcSEcCtD
Goserelin—Photosensitivity reaction—Epirubicin—uterine cancer	0.000289	0.000437	CcSEcCtD
Goserelin—Paraesthesia—Etoposide—uterine cancer	0.000289	0.000436	CcSEcCtD
Goserelin—Weight increased—Epirubicin—uterine cancer	0.000288	0.000436	CcSEcCtD
Goserelin—Dyspnoea—Etoposide—uterine cancer	0.000287	0.000433	CcSEcCtD
Goserelin—Hyperglycaemia—Epirubicin—uterine cancer	0.000286	0.000432	CcSEcCtD
Goserelin—Somnolence—Etoposide—uterine cancer	0.000286	0.000432	CcSEcCtD
Goserelin—Angina pectoris—Doxorubicin—uterine cancer	0.000286	0.000432	CcSEcCtD
Goserelin—Pneumonia—Epirubicin—uterine cancer	0.000284	0.000429	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—CCL2—uterine cancer	0.000283	0.00786	CbGpPWpGaD
Goserelin—Drowsiness—Epirubicin—uterine cancer	0.000283	0.000427	CcSEcCtD
Goserelin—Vomiting—Dactinomycin—uterine cancer	0.000282	0.000427	CcSEcCtD
Goserelin—Bronchitis—Doxorubicin—uterine cancer	0.000282	0.000426	CcSEcCtD
Goserelin—Rash—Dactinomycin—uterine cancer	0.00028	0.000423	CcSEcCtD
Goserelin—Decreased appetite—Etoposide—uterine cancer	0.00028	0.000422	CcSEcCtD
Goserelin—Renal failure—Epirubicin—uterine cancer	0.000278	0.00042	CcSEcCtD
Goserelin—Fatigue—Etoposide—uterine cancer	0.000277	0.000419	CcSEcCtD
Goserelin—Jaundice—Epirubicin—uterine cancer	0.000275	0.000416	CcSEcCtD
Goserelin—Pain—Etoposide—uterine cancer	0.000275	0.000415	CcSEcCtD
Goserelin—Constipation—Etoposide—uterine cancer	0.000275	0.000415	CcSEcCtD
Goserelin—Urinary tract infection—Epirubicin—uterine cancer	0.000275	0.000415	CcSEcCtD
Goserelin—Dysuria—Doxorubicin—uterine cancer	0.000274	0.000414	CcSEcCtD
Goserelin—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000273	0.000412	CcSEcCtD
Goserelin—Sweating—Epirubicin—uterine cancer	0.000271	0.000409	CcSEcCtD
Goserelin—Pollakiuria—Doxorubicin—uterine cancer	0.000271	0.000409	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—INHBA—uterine cancer	0.00027	0.0075	CbGpPWpGaD
Goserelin—Haematuria—Epirubicin—uterine cancer	0.000269	0.000407	CcSEcCtD
Goserelin—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000268	0.000404	CcSEcCtD
Goserelin—Weight increased—Doxorubicin—uterine cancer	0.000267	0.000403	CcSEcCtD
Goserelin—Epistaxis—Epirubicin—uterine cancer	0.000267	0.000403	CcSEcCtD
Goserelin—Sinusitis—Epirubicin—uterine cancer	0.000265	0.0004	CcSEcCtD
Goserelin—Feeling abnormal—Etoposide—uterine cancer	0.000265	0.0004	CcSEcCtD
Goserelin—Hyperglycaemia—Doxorubicin—uterine cancer	0.000265	0.0004	CcSEcCtD
Goserelin—Nausea—Dactinomycin—uterine cancer	0.000264	0.000399	CcSEcCtD
Goserelin—Pneumonia—Doxorubicin—uterine cancer	0.000263	0.000397	CcSEcCtD
Goserelin—Gastrointestinal pain—Etoposide—uterine cancer	0.000263	0.000397	CcSEcCtD
Goserelin—Drowsiness—Doxorubicin—uterine cancer	0.000261	0.000395	CcSEcCtD
Goserelin—Renal failure—Doxorubicin—uterine cancer	0.000257	0.000388	CcSEcCtD
Goserelin—Urticaria—Etoposide—uterine cancer	0.000255	0.000386	CcSEcCtD
Goserelin—Haemoglobin—Epirubicin—uterine cancer	0.000255	0.000385	CcSEcCtD
Goserelin—Jaundice—Doxorubicin—uterine cancer	0.000255	0.000385	CcSEcCtD
Goserelin—Rhinitis—Epirubicin—uterine cancer	0.000254	0.000384	CcSEcCtD
Goserelin—Body temperature increased—Etoposide—uterine cancer	0.000254	0.000384	CcSEcCtD
Goserelin—Abdominal pain—Etoposide—uterine cancer	0.000254	0.000384	CcSEcCtD
Goserelin—Urinary tract infection—Doxorubicin—uterine cancer	0.000254	0.000384	CcSEcCtD
Goserelin—Hepatitis—Epirubicin—uterine cancer	0.000254	0.000383	CcSEcCtD
Goserelin—Haemorrhage—Epirubicin—uterine cancer	0.000254	0.000383	CcSEcCtD
Goserelin—Pharyngitis—Epirubicin—uterine cancer	0.000252	0.00038	CcSEcCtD
Goserelin—Sweating—Doxorubicin—uterine cancer	0.000251	0.000379	CcSEcCtD
Goserelin—Urinary tract disorder—Epirubicin—uterine cancer	0.000251	0.000378	CcSEcCtD
Goserelin—Oedema peripheral—Epirubicin—uterine cancer	0.00025	0.000378	CcSEcCtD
Goserelin—Haematuria—Doxorubicin—uterine cancer	0.000249	0.000377	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000249	0.00691	CbGpPWpGaD
Goserelin—Urethral disorder—Epirubicin—uterine cancer	0.000249	0.000376	CcSEcCtD
Goserelin—Epistaxis—Doxorubicin—uterine cancer	0.000247	0.000373	CcSEcCtD
Goserelin—Sinusitis—Doxorubicin—uterine cancer	0.000245	0.000371	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—AKR1C1—uterine cancer	0.000244	0.00675	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKR1B10—uterine cancer	0.000239	0.00663	CbGpPWpGaD
Goserelin—Eye disorder—Epirubicin—uterine cancer	0.000237	0.000358	CcSEcCtD
Goserelin—Hypersensitivity—Etoposide—uterine cancer	0.000237	0.000358	CcSEcCtD
Goserelin—Haemoglobin—Doxorubicin—uterine cancer	0.000236	0.000356	CcSEcCtD
Goserelin—Cardiac disorder—Epirubicin—uterine cancer	0.000235	0.000356	CcSEcCtD
Goserelin—Rhinitis—Doxorubicin—uterine cancer	0.000235	0.000355	CcSEcCtD
Goserelin—Hepatitis—Doxorubicin—uterine cancer	0.000235	0.000355	CcSEcCtD
Goserelin—Haemorrhage—Doxorubicin—uterine cancer	0.000235	0.000355	CcSEcCtD
Goserelin—Pharyngitis—Doxorubicin—uterine cancer	0.000233	0.000352	CcSEcCtD
Goserelin—Urinary tract disorder—Doxorubicin—uterine cancer	0.000232	0.00035	CcSEcCtD
Goserelin—Oedema peripheral—Doxorubicin—uterine cancer	0.000231	0.000349	CcSEcCtD
Goserelin—Asthenia—Etoposide—uterine cancer	0.000231	0.000348	CcSEcCtD
Goserelin—Angiopathy—Epirubicin—uterine cancer	0.00023	0.000348	CcSEcCtD
Goserelin—Urethral disorder—Doxorubicin—uterine cancer	0.00023	0.000348	CcSEcCtD
Goserelin—Immune system disorder—Epirubicin—uterine cancer	0.000229	0.000346	CcSEcCtD
Goserelin—Chills—Epirubicin—uterine cancer	0.000228	0.000344	CcSEcCtD
Goserelin—Pruritus—Etoposide—uterine cancer	0.000227	0.000344	CcSEcCtD
Goserelin—Arrhythmia—Epirubicin—uterine cancer	0.000227	0.000342	CcSEcCtD
Goserelin—Alopecia—Epirubicin—uterine cancer	0.000224	0.000339	CcSEcCtD
Goserelin—LHCGR—GPCR ligand binding—CXCL8—uterine cancer	0.000224	0.00621	CbGpPWpGaD
Goserelin—Mental disorder—Epirubicin—uterine cancer	0.000222	0.000336	CcSEcCtD
Goserelin—Erythema—Epirubicin—uterine cancer	0.000221	0.000334	CcSEcCtD
Goserelin—Malnutrition—Epirubicin—uterine cancer	0.000221	0.000334	CcSEcCtD
Goserelin—Diarrhoea—Etoposide—uterine cancer	0.00022	0.000332	CcSEcCtD
Goserelin—Eye disorder—Doxorubicin—uterine cancer	0.000219	0.000331	CcSEcCtD
Goserelin—Cardiac disorder—Doxorubicin—uterine cancer	0.000218	0.000329	CcSEcCtD
Goserelin—Flatulence—Epirubicin—uterine cancer	0.000218	0.000329	CcSEcCtD
Goserelin—Tension—Epirubicin—uterine cancer	0.000217	0.000327	CcSEcCtD
Goserelin—Nervousness—Epirubicin—uterine cancer	0.000215	0.000324	CcSEcCtD
Goserelin—Back pain—Epirubicin—uterine cancer	0.000214	0.000323	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	0.000213	0.00592	CbGpPWpGaD
Goserelin—Angiopathy—Doxorubicin—uterine cancer	0.000213	0.000322	CcSEcCtD
Goserelin—Dizziness—Etoposide—uterine cancer	0.000213	0.000321	CcSEcCtD
Goserelin—Muscle spasms—Epirubicin—uterine cancer	0.000212	0.000321	CcSEcCtD
Goserelin—Immune system disorder—Doxorubicin—uterine cancer	0.000212	0.00032	CcSEcCtD
Goserelin—Chills—Doxorubicin—uterine cancer	0.000211	0.000318	CcSEcCtD
Goserelin—Arrhythmia—Doxorubicin—uterine cancer	0.00021	0.000317	CcSEcCtD
Goserelin—Vision blurred—Epirubicin—uterine cancer	0.000208	0.000314	CcSEcCtD
Goserelin—Alopecia—Doxorubicin—uterine cancer	0.000207	0.000313	CcSEcCtD
Goserelin—Mental disorder—Doxorubicin—uterine cancer	0.000206	0.000311	CcSEcCtD
Goserelin—Ill-defined disorder—Epirubicin—uterine cancer	0.000205	0.00031	CcSEcCtD
Goserelin—Vomiting—Etoposide—uterine cancer	0.000204	0.000309	CcSEcCtD
Goserelin—Malnutrition—Doxorubicin—uterine cancer	0.000204	0.000309	CcSEcCtD
Goserelin—Erythema—Doxorubicin—uterine cancer	0.000204	0.000309	CcSEcCtD
Goserelin—Anaemia—Epirubicin—uterine cancer	0.000204	0.000308	CcSEcCtD
Goserelin—Rash—Etoposide—uterine cancer	0.000203	0.000306	CcSEcCtD
Goserelin—Dermatitis—Etoposide—uterine cancer	0.000203	0.000306	CcSEcCtD
Goserelin—Headache—Etoposide—uterine cancer	0.000201	0.000304	CcSEcCtD
Goserelin—Flatulence—Doxorubicin—uterine cancer	0.000201	0.000304	CcSEcCtD
Goserelin—Tension—Doxorubicin—uterine cancer	0.000201	0.000303	CcSEcCtD
Goserelin—Malaise—Epirubicin—uterine cancer	0.000199	0.000301	CcSEcCtD
Goserelin—Nervousness—Doxorubicin—uterine cancer	0.000198	0.0003	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—RNF43—uterine cancer	0.000198	0.00549	CbGpPWpGaD
Goserelin—Leukopenia—Epirubicin—uterine cancer	0.000198	0.000299	CcSEcCtD
Goserelin—Back pain—Doxorubicin—uterine cancer	0.000198	0.000299	CcSEcCtD
Goserelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000197	0.00546	CbGpPWpGaD
Goserelin—Muscle spasms—Doxorubicin—uterine cancer	0.000196	0.000297	CcSEcCtD
Goserelin—Palpitations—Epirubicin—uterine cancer	0.000195	0.000295	CcSEcCtD
Goserelin—Cough—Epirubicin—uterine cancer	0.000193	0.000291	CcSEcCtD
Goserelin—Vision blurred—Doxorubicin—uterine cancer	0.000193	0.000291	CcSEcCtD
Goserelin—Convulsion—Epirubicin—uterine cancer	0.000191	0.000289	CcSEcCtD
Goserelin—Nausea—Etoposide—uterine cancer	0.000191	0.000288	CcSEcCtD
Goserelin—Hypertension—Epirubicin—uterine cancer	0.000191	0.000288	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—CCL2—uterine cancer	0.00019	0.00526	CbGpPWpGaD
Goserelin—Ill-defined disorder—Doxorubicin—uterine cancer	0.00019	0.000286	CcSEcCtD
Goserelin—Anaemia—Doxorubicin—uterine cancer	0.000189	0.000285	CcSEcCtD
Goserelin—GNRHR—G alpha (q) signalling events—PIK3CA—uterine cancer	0.000189	0.00523	CbGpPWpGaD
Goserelin—Arthralgia—Epirubicin—uterine cancer	0.000188	0.000284	CcSEcCtD
Goserelin—Chest pain—Epirubicin—uterine cancer	0.000188	0.000284	CcSEcCtD
Goserelin—Myalgia—Epirubicin—uterine cancer	0.000188	0.000284	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—AKR1C3—uterine cancer	0.000187	0.0052	CbGpPWpGaD
Goserelin—Anxiety—Epirubicin—uterine cancer	0.000187	0.000283	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000187	0.000282	CcSEcCtD
Goserelin—Discomfort—Epirubicin—uterine cancer	0.000186	0.000281	CcSEcCtD
Goserelin—Malaise—Doxorubicin—uterine cancer	0.000184	0.000278	CcSEcCtD
Goserelin—Dry mouth—Epirubicin—uterine cancer	0.000184	0.000278	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	0.000184	0.00509	CbGpPWpGaD
Goserelin—Leukopenia—Doxorubicin—uterine cancer	0.000183	0.000276	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—PGR—uterine cancer	0.000183	0.00507	CbGpPWpGaD
Goserelin—Confusional state—Epirubicin—uterine cancer	0.000182	0.000275	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—INHBA—uterine cancer	0.000181	0.00502	CbGpPWpGaD
Goserelin—Palpitations—Doxorubicin—uterine cancer	0.000181	0.000273	CcSEcCtD
Goserelin—Oedema—Epirubicin—uterine cancer	0.00018	0.000272	CcSEcCtD
Goserelin—Anaphylactic shock—Epirubicin—uterine cancer	0.00018	0.000272	CcSEcCtD
Goserelin—Infection—Epirubicin—uterine cancer	0.000179	0.00027	CcSEcCtD
Goserelin—Cough—Doxorubicin—uterine cancer	0.000178	0.000269	CcSEcCtD
Goserelin—Shock—Epirubicin—uterine cancer	0.000177	0.000268	CcSEcCtD
Goserelin—Convulsion—Doxorubicin—uterine cancer	0.000177	0.000267	CcSEcCtD
Goserelin—Nervous system disorder—Epirubicin—uterine cancer	0.000177	0.000267	CcSEcCtD
Goserelin—Thrombocytopenia—Epirubicin—uterine cancer	0.000176	0.000267	CcSEcCtD
Goserelin—Hypertension—Doxorubicin—uterine cancer	0.000176	0.000266	CcSEcCtD
Goserelin—Tachycardia—Epirubicin—uterine cancer	0.000176	0.000266	CcSEcCtD
Goserelin—Skin disorder—Epirubicin—uterine cancer	0.000175	0.000264	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—YWHAE—uterine cancer	0.000174	0.00483	CbGpPWpGaD
Goserelin—Hyperhidrosis—Epirubicin—uterine cancer	0.000174	0.000263	CcSEcCtD
Goserelin—Arthralgia—Doxorubicin—uterine cancer	0.000174	0.000263	CcSEcCtD
Goserelin—Chest pain—Doxorubicin—uterine cancer	0.000174	0.000263	CcSEcCtD
Goserelin—Myalgia—Doxorubicin—uterine cancer	0.000174	0.000263	CcSEcCtD
Goserelin—Anxiety—Doxorubicin—uterine cancer	0.000173	0.000262	CcSEcCtD
Goserelin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000173	0.000261	CcSEcCtD
Goserelin—Discomfort—Doxorubicin—uterine cancer	0.000172	0.00026	CcSEcCtD
Goserelin—Anorexia—Epirubicin—uterine cancer	0.000172	0.00026	CcSEcCtD
Goserelin—Dry mouth—Doxorubicin—uterine cancer	0.00017	0.000257	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	0.000169	0.00468	CbGpPWpGaD
Goserelin—Hypotension—Epirubicin—uterine cancer	0.000168	0.000254	CcSEcCtD
Goserelin—Confusional state—Doxorubicin—uterine cancer	0.000168	0.000254	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—FBXW7—uterine cancer	0.000167	0.00463	CbGpPWpGaD
Goserelin—Oedema—Doxorubicin—uterine cancer	0.000167	0.000252	CcSEcCtD
Goserelin—Anaphylactic shock—Doxorubicin—uterine cancer	0.000167	0.000252	CcSEcCtD
Goserelin—Infection—Doxorubicin—uterine cancer	0.000166	0.00025	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000164	0.000248	CcSEcCtD
Goserelin—Shock—Doxorubicin—uterine cancer	0.000164	0.000248	CcSEcCtD
Goserelin—Nervous system disorder—Doxorubicin—uterine cancer	0.000164	0.000247	CcSEcCtD
Goserelin—Thrombocytopenia—Doxorubicin—uterine cancer	0.000163	0.000247	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—AKR1C1—uterine cancer	0.000163	0.00452	CbGpPWpGaD
Goserelin—Insomnia—Epirubicin—uterine cancer	0.000163	0.000246	CcSEcCtD
Goserelin—Tachycardia—Doxorubicin—uterine cancer	0.000163	0.000246	CcSEcCtD
Goserelin—Skin disorder—Doxorubicin—uterine cancer	0.000162	0.000245	CcSEcCtD
Goserelin—Paraesthesia—Epirubicin—uterine cancer	0.000162	0.000244	CcSEcCtD
Goserelin—Hyperhidrosis—Doxorubicin—uterine cancer	0.000161	0.000244	CcSEcCtD
Goserelin—Dyspnoea—Epirubicin—uterine cancer	0.000161	0.000243	CcSEcCtD
Goserelin—Somnolence—Epirubicin—uterine cancer	0.00016	0.000242	CcSEcCtD
Goserelin—Anorexia—Doxorubicin—uterine cancer	0.000159	0.00024	CcSEcCtD
Goserelin—Dyspepsia—Epirubicin—uterine cancer	0.000159	0.00024	CcSEcCtD
Goserelin—Decreased appetite—Epirubicin—uterine cancer	0.000157	0.000237	CcSEcCtD
Goserelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	0.000156	0.00433	CbGpPWpGaD
Goserelin—Hypotension—Doxorubicin—uterine cancer	0.000156	0.000235	CcSEcCtD
Goserelin—Fatigue—Epirubicin—uterine cancer	0.000155	0.000235	CcSEcCtD
Goserelin—Pain—Epirubicin—uterine cancer	0.000154	0.000233	CcSEcCtD
Goserelin—Constipation—Epirubicin—uterine cancer	0.000154	0.000233	CcSEcCtD
Goserelin—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000152	0.00023	CcSEcCtD
Goserelin—Insomnia—Doxorubicin—uterine cancer	0.000151	0.000228	CcSEcCtD
Goserelin—GNRHR—GPCR ligand binding—CXCL8—uterine cancer	0.00015	0.00416	CbGpPWpGaD
Goserelin—Paraesthesia—Doxorubicin—uterine cancer	0.00015	0.000226	CcSEcCtD
Goserelin—Dyspnoea—Doxorubicin—uterine cancer	0.000149	0.000225	CcSEcCtD
Goserelin—Feeling abnormal—Epirubicin—uterine cancer	0.000149	0.000224	CcSEcCtD
Goserelin—Somnolence—Doxorubicin—uterine cancer	0.000148	0.000224	CcSEcCtD
Goserelin—Gastrointestinal pain—Epirubicin—uterine cancer	0.000147	0.000223	CcSEcCtD
Goserelin—Dyspepsia—Doxorubicin—uterine cancer	0.000147	0.000222	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—STK11—uterine cancer	0.000146	0.00405	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CCL2—uterine cancer	0.000145	0.00403	CbGpPWpGaD
Goserelin—Decreased appetite—Doxorubicin—uterine cancer	0.000145	0.000219	CcSEcCtD
Goserelin—Fatigue—Doxorubicin—uterine cancer	0.000144	0.000217	CcSEcCtD
Goserelin—Urticaria—Epirubicin—uterine cancer	0.000143	0.000216	CcSEcCtD
Goserelin—Pain—Doxorubicin—uterine cancer	0.000143	0.000215	CcSEcCtD
Goserelin—Constipation—Doxorubicin—uterine cancer	0.000143	0.000215	CcSEcCtD
Goserelin—Body temperature increased—Epirubicin—uterine cancer	0.000142	0.000215	CcSEcCtD
Goserelin—Abdominal pain—Epirubicin—uterine cancer	0.000142	0.000215	CcSEcCtD
Goserelin—Feeling abnormal—Doxorubicin—uterine cancer	0.000137	0.000208	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—SOCS3—uterine cancer	0.000137	0.00379	CbGpPWpGaD
Goserelin—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000136	0.000206	CcSEcCtD
Goserelin—Hypersensitivity—Epirubicin—uterine cancer	0.000133	0.000201	CcSEcCtD
Goserelin—Urticaria—Doxorubicin—uterine cancer	0.000132	0.0002	CcSEcCtD
Goserelin—Abdominal pain—Doxorubicin—uterine cancer	0.000132	0.000199	CcSEcCtD
Goserelin—Body temperature increased—Doxorubicin—uterine cancer	0.000132	0.000199	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—CDKN2B—uterine cancer	0.000131	0.00363	CbGpPWpGaD
Goserelin—Asthenia—Epirubicin—uterine cancer	0.000129	0.000195	CcSEcCtD
Goserelin—Pruritus—Epirubicin—uterine cancer	0.000128	0.000193	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—IGF1R—uterine cancer	0.000127	0.00353	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—CXCL8—uterine cancer	0.000127	0.00351	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKR1C3—uterine cancer	0.000126	0.00348	CbGpPWpGaD
Goserelin—Diarrhoea—Epirubicin—uterine cancer	0.000123	0.000186	CcSEcCtD
Goserelin—Hypersensitivity—Doxorubicin—uterine cancer	0.000123	0.000186	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—PGR—uterine cancer	0.000122	0.00339	CbGpPWpGaD
Goserelin—Asthenia—Doxorubicin—uterine cancer	0.00012	0.000181	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—SMAD3—uterine cancer	0.00012	0.00332	CbGpPWpGaD
Goserelin—Dizziness—Epirubicin—uterine cancer	0.000119	0.00018	CcSEcCtD
Goserelin—Pruritus—Doxorubicin—uterine cancer	0.000118	0.000178	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—YWHAE—uterine cancer	0.000117	0.00324	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—CXCL8—uterine cancer	0.000115	0.00319	CbGpPWpGaD
Goserelin—Vomiting—Epirubicin—uterine cancer	0.000115	0.000173	CcSEcCtD
Goserelin—Diarrhoea—Doxorubicin—uterine cancer	0.000114	0.000172	CcSEcCtD
Goserelin—LHCGR—Signaling Pathways—FGFR2—uterine cancer	0.000114	0.00316	CbGpPWpGaD
Goserelin—Rash—Epirubicin—uterine cancer	0.000114	0.000172	CcSEcCtD
Goserelin—Dermatitis—Epirubicin—uterine cancer	0.000114	0.000172	CcSEcCtD
Goserelin—Headache—Epirubicin—uterine cancer	0.000113	0.000171	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—FBXW7—uterine cancer	0.000112	0.0031	CbGpPWpGaD
Goserelin—Dizziness—Doxorubicin—uterine cancer	0.00011	0.000167	CcSEcCtD
Goserelin—Nausea—Epirubicin—uterine cancer	0.000107	0.000162	CcSEcCtD
Goserelin—Vomiting—Doxorubicin—uterine cancer	0.000106	0.00016	CcSEcCtD
Goserelin—Rash—Doxorubicin—uterine cancer	0.000105	0.000159	CcSEcCtD
Goserelin—Dermatitis—Doxorubicin—uterine cancer	0.000105	0.000159	CcSEcCtD
Goserelin—Headache—Doxorubicin—uterine cancer	0.000104	0.000158	CcSEcCtD
Goserelin—Nausea—Doxorubicin—uterine cancer	9.91e-05	0.00015	CcSEcCtD
Goserelin—GNRHR—Signaling Pathways—STK11—uterine cancer	9.78e-05	0.00271	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ESR1—uterine cancer	9.76e-05	0.00271	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CCL2—uterine cancer	9.73e-05	0.0027	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—NRAS—uterine cancer	9.22e-05	0.00256	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SOCS3—uterine cancer	9.16e-05	0.00254	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CDKN2B—uterine cancer	8.77e-05	0.00243	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CCL2—uterine cancer	8.59e-05	0.00238	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—IGF1R—uterine cancer	8.51e-05	0.00236	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—CXCL8—uterine cancer	8.47e-05	0.00235	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—PIK3CA—uterine cancer	8.03e-05	0.00223	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—SMAD3—uterine cancer	8e-05	0.00222	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—KRAS—uterine cancer	7.94e-05	0.0022	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—CXCL8—uterine cancer	7.7e-05	0.00213	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—FGFR2—uterine cancer	7.63e-05	0.00212	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—PIK3CA—uterine cancer	7.29e-05	0.00202	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—ERBB2—uterine cancer	7.16e-05	0.00199	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CXCL8—uterine cancer	6.79e-05	0.00188	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—HRAS—uterine cancer	6.75e-05	0.00187	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CDKN1B—uterine cancer	6.63e-05	0.00184	CbGpPWpGaD
Goserelin—LHCGR—GPCR downstream signaling—AKT1—uterine cancer	6.56e-05	0.00182	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ESR1—uterine cancer	6.53e-05	0.00181	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—CTNNB1—uterine cancer	6.27e-05	0.00174	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—NRAS—uterine cancer	6.17e-05	0.00171	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PTEN—uterine cancer	6.11e-05	0.00169	CbGpPWpGaD
Goserelin—LHCGR—Signaling by GPCR—AKT1—uterine cancer	5.96e-05	0.00165	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—EP300—uterine cancer	5.82e-05	0.00162	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CCL2—uterine cancer	5.75e-05	0.00159	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—VEGFA—uterine cancer	5.52e-05	0.00153	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—NRAS—uterine cancer	5.45e-05	0.00151	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—PIK3CA—uterine cancer	5.38e-05	0.00149	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—KRAS—uterine cancer	5.31e-05	0.00147	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—PIK3CA—uterine cancer	4.88e-05	0.00135	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—ERBB2—uterine cancer	4.79e-05	0.00133	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—KRAS—uterine cancer	4.69e-05	0.0013	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CXCL8—uterine cancer	4.55e-05	0.00126	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—HRAS—uterine cancer	4.52e-05	0.00125	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CDKN1B—uterine cancer	4.44e-05	0.00123	CbGpPWpGaD
Goserelin—GNRHR—GPCR downstream signaling—AKT1—uterine cancer	4.39e-05	0.00122	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—PIK3CA—uterine cancer	4.31e-05	0.00119	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—CTNNB1—uterine cancer	4.19e-05	0.00116	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—TP53—uterine cancer	4.17e-05	0.00116	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PTEN—uterine cancer	4.09e-05	0.00113	CbGpPWpGaD
Goserelin—GNRHR—Signaling by GPCR—AKT1—uterine cancer	3.99e-05	0.00111	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—HRAS—uterine cancer	3.99e-05	0.00111	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—EP300—uterine cancer	3.9e-05	0.00108	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—VEGFA—uterine cancer	3.69e-05	0.00102	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—NRAS—uterine cancer	3.65e-05	0.00101	CbGpPWpGaD
Goserelin—LHCGR—Signaling Pathways—AKT1—uterine cancer	3.52e-05	0.000976	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—KRAS—uterine cancer	3.14e-05	0.000871	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—PIK3CA—uterine cancer	2.88e-05	0.0008	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—TP53—uterine cancer	2.79e-05	0.000774	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—HRAS—uterine cancer	2.67e-05	0.00074	CbGpPWpGaD
Goserelin—GNRHR—Signaling Pathways—AKT1—uterine cancer	2.36e-05	0.000653	CbGpPWpGaD
